The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues

DSpace/Manakin Repository

The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues

Citable link to this page

. . . . . .

Title: The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues
Author: Kaufman, Robert
Citation: The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues (2004 Third Year Paper)
Full Text & Related Files:
Abstract: The regulation off-label drugs is a complicated and controversial area of the law. Regulators must protect patients’ safety without interfering with physicians’ practice of medicine or manufacturers’ First Amendment rights. The recent Neurontin decisions, which apply the doctrine of false claims to prescription drug regulation, only adds additional complexity. This paper explores the federal government’s attempts to regulate the promotion of off-label drugs. It discussed the advantages and disadvantages of off-label marketing, the current regulatory environment, and the implications of the Neurontin lawsuit.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8963868

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters